Using a mouse model of mammary gland development and tumorigenesis we examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to in¯uence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias diered as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little dierence was observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of speci®c splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to aect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.
Introduction
Alternate pre-mRNA processing contributes significantly to the developmental regulation of gene expression in humans. It is estimated that as many as 25% of human genes utilize alternative RNA processing to produce subtly or grossly altered gene products (Moore et al., 1993; Rio, 1993; Norton, 1994; Berget, 1995; Kramer, 1996) . During the last year, reports have emerged indicating that cancerogenesis induces changes in alternative processing (Lee and Feinberg, 1997; Silberstein et al., 1997; Zhu et al., 1997) . Some of the genes targeted for these changes are receptor proteins suggesting that the induced alterations in splicing could have pronounced consequences for cellular behavior. Little, however is known about how RNA processing factors are altered during tumorigenesis so as to aect processing outcomes.
The arginine-serine-rich (SR) proteins ( Figure 1a ) constitute a family of essential splicing factors (Krainer et al., 1990a; Ge et al., 1991; Zahler et al., 1992) that recognize both splice sites and exonic splicing enhancers, and in¯uence alternative processing decisions when their relative concentrations are altered in vivo or in vitro (Ge and Manley, 1990; Krainer et al., 1990b; Zahler et al., 1993a; CaÂ ceres et al., 1994; Wang and Manley, 1995) . SR proteins have been observed to in¯uence splicing activity via their binding to both splice sites and special splicing accessory sequences known as enhancers (Zahler et al., 1993b; Fu, 1995; Manley and Tacke, 1996; Valcarcel and Green, 1996) . Recent studies have indicated substrate-speci®c binding and activity for individual SR proteins (Fu, 1993; Sun et al., 1993; Zahler et al., 1993a; CaÂ ceres et al., 1994; Wang and Manley, 1995; Chandler et al., 1997; Liu et al., 1998) . Furthermore, individual SR proteins have distinct tissue distributions (Zahler et al., 1992; Screaton et al., 1995; CaÂ ceres and Krainer, 1997) . These observations have led to suggestions that alterations in the levels of SR proteins could be determinative for alternative splicing during development. This class of proteins, therefore, become attractive candidates for factors whose activity changes during tumorigenesis.
An ideal system in which to study the relationship between processing and the progression of cancer would be one in which both normal and abnormal development could be compared and studied in an isogenic and manipulatable background. Such a system is available in an established in vivo mouse model of mammary tumorigenesis (Kittrell et al., 1992; Medina, 1996) that provides access to normal mammary tissues from mature virgin, pregnant and lactating females, as well as an extensively characterized set of preneoplasias and their corresponding adenocarcinomas and metastases. In this model system, preneoplastic outgrowth lines are serially transplanted and maintained for extended periods of time (up to 12 months) in the mammary fat pads of syngenic female BALB/c mice. Each outgrowth line is characterized by a speci®c rate for development of adenocarcinomas and subsequent metastases (Kittrell et al., 1992; Medina, 1996) . The outgrowths are clonal cell populations as determined by oncogene analysis (Cardi, 1988; Jerry et al., 1993) .
Using this system, we characterized SR protein expression during tumorigenesis. At the same time we examined the alternative splicing of a pre-mRNA, that coding for CD44, whose splicing had been reported to be determinative for metastasis (Gunthert et al., 1991) . CD44, is a widely expressed cell adhesion molecule and trans-membrane glycoprotein that mediates a variety of cell-cell and cell matrix interactions (Fox et al., 1994; Mackay et al., 1994; Stamenkovic et al., 1989) . A number of CD44 isoforms are created via alternative pre-mRNA splicing. Within the CD44 gene is an internal cassette of ten alternatively spliced exons, all in the same translational reading frame, and coding for speci®c extracellular domains of the CD44 protein (Screaton et al., 1992; Figure 1b) . Combinations of these variable exons lead to a variety of CD44 isoforms (Screaton et al., 1992; Haynes et al., 1990; Gunthert, 1993) . Certain isoforms, especially those including variable exons v5, 6, and 7, have been implicated in the metastasis of several malignancies (East and Hart, 1993; Cannistra et al., 1995; Stickeler et al., 1997; Wielenga et al., 1993) and correlated with survival in human breast cancer (Joensuu et al., 1993; Kaufmann et al., 1995) . Recently it has been shown that alternative splicing of CD44 responds to signal transduction. Treatment of T-lymphoma cells that normally express a form of CD44 lacking variable exons, with phorbol esters, concanavalin A, or c-ras induces inclusion of variable exons (KoÈ nig et al., 1998) . Thus, alternative splicing of CD44 may be involved in malignant transformation of tissues during tumorigenesis, and CD44 joins the collection of genes whose splicing is altered during cancer (Lee and Feinberg, 1997; Zhu et al., 1997; Silberstein et al., 1997) .
Recently it has been shown that CD44 alternative splicing may involve inclusion of blocks of alternative exons rather than single isolated exons (Bell et al., 1998) . As the metastatic potential of CD44 has been correlated with only a single variable exon, it becomes of interest to see if the pattern of CD44 variable expression during tumorigenesis may have been underestimated by the heavy attention directed to this one exon.
Here we report that step-wise alterations in SR splicing factor levels and CD44 alternative splicing accompanied the transition from normal cells through preneoplasia and mammary adenocarcinoma, but not metastases. Individual preneoplasias exhibited differences in their SR expression pattern and limited CD44 alternative splicing. Alternative splicing of a control gene was not aected during preneoplasia or neoplasia, suggesting gene-speci®c alterations in RNA processing factors during early tumorigenesis, rather than a general increase in the generic processing machinery. Tumors showed high levels of SR proteins, including proteins never expressed in virgin mammary epithelia and high levels of inclusion of a variety of CD44 alternative exons. Our results suggest that alterations in alternative processing may be important features of early and intermediate stages of mammary cancer.
Results
For this study, a number of mammary preneoplasias and tumors were utilized, including tumors and metastases derived from two of the preneoplasias. The tumorigenic and metastatic properties of two of the preneoplastic outgrowth lines, TM-2L and TM-40, are summarized in Table 1 . Both TM-2L and TM-40 produce type B mammary adenocarcinomas by 12 months, at an incidence of 21 or 51%, respectively. The main dierence between the two lines is the signi®cant metastatic growth, primarily in lungs and occasionally in liver, of TM-40 (Table 2) .
Stepwise alterations in expression of SR proteins during development of mammary cancer SR proteins are essential splicing factors that participate in early events of substrate recognition by the processing machinery (Fu, 1995; Zahler et al., 1993a,b; Manley and Tacke, 1996 ; Valcarcel and Green, 1996) . In addition they bind to accessory splicing enhancer sequences to facilitate splicing of alternative exons (Ge and Manley, 1990; CaÂ ceres et al., 1994; Wang and Manley, 1995) . SR proteins are characterized by an extensive region containing arginine and serine ( Figure 1a ) which is extensively phosphorylated. Within this phosphorylated domain is the epitope for a monoclonal antibody, mAb104 (Zahler et al., 1993b; Valcarcel and Green, 1996) . To examine alterations in splicing factors during development of mammary cancer, we examined the expression of SR proteins in normal and neoplastic mammary tissues by Western blots using mAb104. In HeLa cells, mAb104 recognizes approximately equal amounts of the major SR proteins (SRp20, ASF/SF2, SC35, 9G8, SRp30c, SRp40, SRp55, and SRp75 of molecular weights 20 ± 75 kDa, Zahler et al., 1993b) . Mammary epithelial cells from mature virgin glands expressed a sub-set of the major SR proteins, yielding dominant expression of SRp75 and SRp55 (Figure 2a, lane 1) . Three of the preneoplasias, TM-2L, TM-4 and TM-10, yielded an SR expression pattern similar to that of mature, virgin mammary gland ( Figure 2a , lanes 2, 4 and 5). The other tested preneoplasias, TM-3 and TM-40, in addition, demonstrated detectable levels of SRp40 and SR proteins of the 30 kDa class, suggesting induction of synthesis of these SR proteins during the preneoplastic process (Figure 2a , lanes 3 and 6). Tested adenocarcinomas and their metastases resembled the expression pattern of HeLa cells, characterized by expression of a broad spectrum of SR proteins detected by mAb104 (Figure 2a , lanes 7 ± 9 and data not shown). We have tested a number of independently derived neoplasia for their SR expression pro®le (data not shown). All demonstrated SR expression patterns identical to those shown in Figure  2a , lanes 7 ± 9, indicating that SR protein expression is induced during tumorigenesis regardless of the expression pattern during pre-neoplasia. Thus, the pattern of SR expression became more complex as neoplasia progressed until a complex array of SR proteins were expressed in tumor cells.
The expression of several control RNA binding factors was monitored over the same disease paradigm. Individual preneoplasias showed identical levels of the 65 kDa subunit of U2AF (Figure 2b ), hnRNP A1 ( Figure 3b ) and hnRNP A2 (Figure 4) , as well as small nuclear ribonucleoproteins (snRNPs) (data not shown), indicating that there was not a general increase in the expression of factors involved in pre-mRNA splicing during preneoplasia. Tumors did show a slight increase (estimated to be twofold) for many factors as Metastases were detected primarily in lung and secondarily in liver in mice 6 ± 8 weeks after surgical removal of the primary tumors (11/15 animals). Metastases are rarely detected in animals bearing primary tumors Figure 2 The expression of SR proteins is altered in mammary adenocarcinomas and in some preneoplasias. (a) Western blot analysis of SR protein expression in dierent breast tissues using an antibody speci®c for a phosphorylated SR epitope (mAb104). Lane 1, mature, virgin gland; lanes 2 ± 6, preneoplasias TM-2L, TM-3, TM-4, TM-10 and TM-40, respectively; lanes 7 ± 9 mammary adenocarcinomas T-5839, T-7780 and T-6129, respectively. Twice as much protein (100 mg) was analysed for normal and preneoplastic tissue (lanes 1 ± 6) than for tumors (50 mg, lanes 7 ± 9). (b) Western blot analysis of the same tissue analysed in (a) for the presence of the constitutive splicing factor U2AF using a polyclonal rabbit antibody raised against a recombinant fragment of the human 65 kDa subunit missing the SR domain (Zamore et al., 1992) . One of the SR proteins induced upon tumorigenesis was SRp20. This protein is only weakly detected by mAb104. By Western blotting, this protein was essentially undetectable in preneoplasias. Neoplasias weakly showed production of SRp20. To better examine induction of this factor we used an antibody speci®c for SRp20. This antibody was raised against an SRp20 peptide from the region of the protein located between the RNA-binding domain and the phosphorylated SR region (Neugebauer and Roth, 1997) . As shown in Figure 2c , SRp20 levels detected by this antibody resembled those detected by the mAb104 antibody. No expression of SRp20 protein was detected in virgin or preneoplastic gland. In contrast, SRp20 was expressed in tumor tissue. To rule out the possibility of a false positive resulting from the presence of endothelial cells or in®ltrating inflammatory cells in the excised adenocarcinomas, we analysed SR protein levels in cultured mammary epithelial cells established from the tumors in this study. In parallel with the tumours, each cell line demonstrated high levels of the entire family of SR proteins recognized by mAb104 (data not shown).
To provide more sensitive detection of SRp20, we monitored SRp20 mRNA levels using RT ± PCR (Figure 2d ). To control for non-linear estimations of mRNA levels using RT ± PCR, SRp20 mRNA levels were also determined by RNase protection (data not shown). As observed by analysis with the Western blotting, tumorigenesis was accompanied by a major increase in the levels of SRp20 mRNAs, indicating that the increased levels of SRp20 in tumors seen with Western blotting re¯ected increased mRNA synthesis rather than increased phosphorylation of an existing protein population (Figure 2d ).
RT ± PCR revealed the presence of a low level of the tested SRp20 mRNAs in the TM-40 preneoplasia that had not been detected by Western blotting, suggesting that low level synthesis of SRp20 occurs in the TM-40 preneoplasia. Even using the power of PCR ampli®cation, however, no SRp20 was detected in preneoplasia TM-2L or in mature virgin tissue. These results indicate that SRp20 is induced during development of mammary carcinogenesis. Furthermore, it indicates a progressive increase in expression as normal cells alter to preneoplasias and then to tumors.
The splicing of CD44 changes during progression of mammary cancer
Alteration in the relative levels of members of the SR proteins recognized by mAb104 is known to aect splicing phenotypes. Thus, the changes in overall amount and, more importantly, in relative amounts of the SR proteins displayed in Figure 2 should be accompanied by changes in alternative processing of target genes. To examine this possibility we looked at the splicing of CD44, a gene with multiple alternative exons. Some of these exons have sequences similar to the purine-rich splicing enhancers known to be the binding sites for the mAB104-reactive SR proteins (Black, 1995; Manley and Tacke, 1996; Reed, 1996; Rio, 1993; Bell et al., 1998; Liu et al., 1998) . Splicing of CD44 was monitored by RT ± PCR analysis of RNA from the same tissues used to examine SR proteins. CD44 mRNA is expressed as two basic forms, with or without one or more of the alternative internal exons. Expression of CD44 standard lacking all variable exons (CD44 std) was examined using primers complementary to constitutive exons 5 and 16, which border the central region of the CD44 gene encoding the ten alternative exons (Figure 1b) . RT ± PCR of CD44 Figure  1b ) inclusion of multiple variable exons produces an ampli®cation pattern with a ladder of bands diering in length by the average variable exon length (approximately 115 nucleotides). This approach permits evaluation of the overall amount of CD44 mRNA present in examined tissues as well as an estimation of the extent of alternative splicing. Ampli®cation revealed that mRNA encoding for CD44 std, lacking the variable exons, was expressed in all tissues examined (Figure 3) . Tumor RNA from adenocarcinomas or their metastases demonstrated noticeable alternative processing to reveal a family of amplification bands resulting from the inclusion of multiple variable exons.
To distinguish CD44-speci®c eects on alternative splicing associated with neoplastic transformation from generic eects on splicing activity associated with an accelerated growth rate, we examined the amounts and spliced isoforms of an RNA that undergoes stochastic alternative splicing in many tissues. The hnRNP A2 gene is processed to produce two mRNA isoforms which alternatively include a 36 nucleotide variable exon. We observed relatively equal levels of total hnRNPA2 mRNA in all tissues examined and approximately equal relative levels of inclusion of the variable exon (Figure 4 ). This result suggests that the changes in CD44 splicing occurring in mammary neoplasia is due to a change in the sub-set of splicing factors required to recognize the CD44 alternative exons and not a change in the generic splicing machinery.
CD44 metastatic exons are expressed at dierent levels during normal mammary gland development and tumorigenesis Low-cycle RT ± PCR with primers speci®c for constitutive exons 5 and 16 produces complicated amplification patterns because of the potential complexity of the family of CD44 mRNA sequences. To better examine variable exons splicing, RNAs from tissue samples were analysed by RT ± PCR using exon-speci®c primers for variable exons 5, 6, 7 or 8 and a consistent primer for constitutive exon 5 (Figure 5a ± d) , followed by cloning and subsequent sequencing of the PCR products. This approach allowed examination of the inclusion of all alternative exons in the interval v1 ± v8. Both low and high cycle ampli®cations were performed. We concentrated on analysis of species containing variable exons v5, 6 or 7, because these exons have been associated with metastasis in other studies (Stickeler et al., 1997; Heider et al., 1995; Sinn et al., 1995) . Variable exon v8 was also of interest because it is one of three so-called`epithelial`exons, included in CD44 mRNA in a variety of epithelial cells.
Low cycle RT ± PCR analysis of RNA from multiple tumors or their metastases using a primer speci®c for variable exon 5 (v5) indicated considerable production of RNAs containing v5 with or without other upstream variable exons (Figure 5a and data not shown). The inclusion patterns for all of the examined tumors and metastases were very similar, and indicated that most of the observed RNA included multiple variable exons from the v1 ± v5 region. In contrast, levels of inclusion of v5 were lower in normal dividing cells from pregnant or lactating mammary gland and in the two tested preneoplasias. Using 25 ± 35 cycles of RT ± PCR (Figure 5a and b) , the major ampli®ed species in these tissues included either v5 alone or v5 and one other upstream variable exon. Cloning and sequencing of the larger ampli®cation band indicated that 4/5 sequenced clones contained v4 in addition to v5. This species was more obvious in pregnant and lactating RNA than in RNA from the preneoplasias (Figure 5a ). We were unable to detect any RNA containing v5 in RNA isolated from mature virgin mammary gland ( Figure  5a , lane 3; and 5b, lane 2). Because of the abundance of fat tissue in mature virgin gland, we isolated epithelial cells from the extracted virgin mammary tissue. High cycle ampli®cation of this RNA yielded no demonstrable inclusion of exon v5 either (data not shown). Therefore, for v5 splicing, three patterns of inclusion were observed by RT ± PCR and sequencing: high level of inclusion of multiple exons along with v5 in tumor cells, low level of inclusion of v5 or v5+4 in preneoplasias, and no inclusion of v5 in normal virgin mammary gland. This pattern suggests step-wise alterations in CD44 alternative splicing during neoplasia. In addition, our data suggest that preneoplasias adopt a splicing pattern similar to that induced in mammary epithelia during normal mammary development and that tumorigenesis is accompanied by induction of a pattern of frequent alternative splicing not found in normal development.
Analysis of alternative splicing of v6 or 7 gave results similar to that discussed above for v5 (Figure 5c and data not shown). Inclusion of both exons occurred at high frequency along with other upstream exons in tumor cell RNA. RNA from preneoplasias and pregnant gland demonstrated simpler RNAs containing fewer variable exons. Sequencing of PCR products indicated that for v6, these RNAs contained only v6. For v7, species containing v7 or v7+4 were observed. In contrast to v5, both v6 and 7 were included in RNA from mature virgin gland epithelial cells ( Figure 5c , lane 5; and data not shown). Like v5, these observations suggest that splicing in preneoplasias is similar to splicing in normal proliferative mammary gland and that the conversion to neoplasia is accompanied by pronounced increased in mRNA including these variable exons. Therefore, for this system of mammary neoplasia, inclusion of v6 is not a marker for either tumorigenesis or metastasis. Instead, a better marker is increased inclusion of a number of CD44 variable exons including v6.
A recent report (Bell et al., 1998) indicated that inclusion of blocks of variable CD44 exons was a frequent phenotype in mice. Such multiple inclusion events are certainly consistent with the patterns we observed in the tumors. Preneoplasias and mature virgin mammary epithelial cells, however, demonstrated inclusion of individual exons without inclusion of an immediate neighbor. For example, v6 was included without v5 in mature gland and preneoplasias and v7 was included with v4 but not v6 and 5. If inclusion of multiple exons re¯ects a mechanism change with respect to inclusion of single exons, then tumorigenesis is accompanied by this mechanism change.
Analysis of RNA for the presence of v8 yielded a surprising result. Like the other variable exons, v8 was included in a number of RNA species in mammary tumor cells (Figure 5d , lanes 5 ± 6). Unlike v5 ± 7, however, no v8 inclusion could be observed in preneoplasias or RNA from developing mammary, despite their epithelial origin (Figure 5d, lanes 3 ± 4) . The observation of induction of v8 splicing in tumor RNA indicates that tumorigenesis is accompanied by alterations in RNA processing of CD44 that are never seen in normal development.
Discussion
During the last several years, studies have suggested changes in pre-mRNA splicing in human malignancies (Lee and Feinberg, 1997; Zhu et al., 1997; Silberstein et al., 1997) . Using an in vivo model of mammary development and tumorigenesis, we were able to study these questions with a focus on comparing splicing phenotypes and factors during normal mammary development to those occurring in development of mammary cancer. Neoplasia was accompanied by a dramatic increase in expression of some of the SR family of splicing factors recognized by mAb104, resulting in alteration of the relative abundance of individual SR proteins and an increase in the complexity of expression of this important class of splicing factors. Given the number of genes whose splicing has been observed to be responsive to relative SR protein levels (Ge and Manley, 1990; Krainer et al., 1990b; CaÂ ceres et al., 1994; Wang and Manley, 1995) , this observation suggests that pronounced changes in alternative splicing of a number of pre-mRNAs should accompany mammary tumorigenesis.
The utilized model system also permitted examination of SR protein expression in preneoplasias with diering capacity to form tumors or for those tumors to metastasize. The preneoplasias characterized in this study diered in their SR protein expression pattern. Some of the neoplasias had mAb104-reactive SR expression patterns similar to that seen with virgin mammary tissue. The tested preneoplasias therefore appeared to represent dierent stages in the transition from normal to tumor tissue with respect to SR protein expression. The utilized preneoplasias arose independently and have dierent tumor and metastasis producing capabilities. SR expression levels did not correlate to tumor or metastatic incidence frequency. Thus, although SR expression changes may be a marker for preneoplasia, they are not predictive for tumor incidence or invasiveness.
Analysis of other constitutive splicing factors indicated that the changes in SR expression we observed were not the result of induction of all splicing during neoplasia. Levels of the constitutive factors U2AF65, two hnRNP proteins, and U snRNPs were only modestly altered during preneoplasia and neoplasia. Therefore, the alterations we observed occurred in a family of factors associated with alternative splicing and the recognition of exon enhancer sequences. This observation suggests that the splicing of multiple target genes regulated by SR proteins would be expected to be altered in neoplasia, without a general eect on exon inclusion levels.
We also used this model to investigate potential changes in alternative splicing in a gene whose splicing changes during cancer have been correlated to metastatic potential in human cancers and which has recently been shown to alter its splicing pattern in response to signal transduction (KoÈ nig et al., 1998) . As with SR proteins, striking increases in alternative splicing of CD44 were observed in adenocarcinomas as compared to either preneoplasias or proliferative mammary epithelia from pregnant animals. All of the tumors examined displayed a similar pattern of exon inclusion, in which multiple alternative exons were included in mRNA. Included in this set of exons were exons not normally present in epithelia of pregnant mammary gland or in preneoplasias. The splicing pattern of the adenocarcinomas was similar to that of the lung and liver metastases of these tumors, indicating few changes accompanying metastasis. In contrast to CD44 alternative splicing, the splicing of a control RNA did not change during the transition from preneoplasia to neoplasia. This dierence suggests that the pronounced changes in splicing of CD44 observed during development of neoplasia arise from the induction of specialized splicing factors, not an increase in the generic splicing machinery.
Although pronounced changes in CD44 splicing correlated with alterations in the expression level of SR proteins during the tumorigenesis paradigm used in this study, it is not yet clear if the two are related. Transfection of cells that normally skip CD44 variable exons 4 and 5 with cDNAs for SRp55 and ASF/SF2 had little eect on exon inclusion in a co-transfected mini-gene containing these two exons (data not shown). In contrast, transfection with cDNAs for both SC35 and tra2 did alter the percentage of exon inclusion (Stickeler and Berget, manuscript in preparation) . Therefore, the splicing of CD44 may be regulated by a sub-set of the SR family of splicing factors.
When we examined CD44 variable exon splicing in epithelia from pregnant mammary gland, we observed low levels of inclusion of some but not all the variable exons. In particular, v6 and 7 were present in a subpopulation of CD44 mRNA from both pregnant tissue and preneoplasias, indicating that these so-called metastatic' exons are included in non-cancerous mammary epithelial cells. In contrast, one variable exons, v5, was not expressed in virgin mammary gland, indicating that alterations in CD44 alternative splicing can occur during preneoplasia and resemble those occurring during pregnancy. Other variable exons that are not included in pregnant tissue (such as thè epithelial' exon v8) are also not expressed during preneoplasia, but are included in tumor RNA. Therefore, our analysis suggests that preneoplasias demonstrate a splicing pattern resembling that occurring during normal breast development. Known to participate in cell-cell interactions and cell-matrix interactions, CD44 isoforms could be involved in the ductal outgrowth occurring during early pregnancy.
Inclusion of three of the CD44 variable exons (v5, 6 and 7) have been postulated to be markers for metastasis potential in several human cancers, including breast cancer. The initial interest in these exons arose from an elegant experiment demonstrating that transfection of a CD44 cDNA including exon v6 into a tumor cell of no metastatic potential increased the rate of metastasis when these cells were placed back into syngenic animals. Such experiments expressed the variant CD44 mRNA at high levels. Our analysis would suggest that the major change in CD44 splicing occurs during development of adenocarcinomas, not their metastases and that it may be the over-expression of variant CD44 mRNAs during the neoplastic state which is important for the metastatic process, rather than the production of any mRNA including v6. This dierence may suggest why experiments monitoring inclusion of CD44 variable exons have failed to demonstrate a consistent correlation to disease progression in several clinical studies (Friedrichs et al., 1995; Muller et al., 1997; Tran et al., 1997) .
The recent report of a coupling between signal transduction and alternative splicing of CD44 concentrated on variable exon v5. Inclusion of this exon showed a pronounced response to induction by c-ras, TPA, or phorbol esters (KoÈ nig et al., 1998) . Exon v5 contains internal sequences that resemble known purine-rich exon enhancers that bind SR proteins. These observations suggest that signal transduction cascades can lead to an induction of SR proteins needed for CD44 variable splicing. In light of these ®ndings, our observation that inclusion of v5 is changed upon preneoplasia supports a possible connection between SR protein levels and CD44 alternative splicing.
Besides CD44 a number of other genes show altered RNA processing during tumorigenesis. A number of cellular receptors and hormone genes undergo alternative processing and this processing appears to alter during cancer. Because the changes in these proteins caused by alternative processing can have a pronounced eect on cellular function, it is important to understand the role of alternative processing in cancer and the mechanisms involved. Determination of splicing factor constellations patterns in preneoplastic lesions of the mammary gland could be very helpful to identify patients in high-risk situations to develop invasive breast cancer and subsequent organ metastasis. Distinct expression patterns of splicing factors could serve as new markers for metastasis in breast cancer, and splicing factors may represent targets for intervention in a subgroup of patients abnormally expressing certain factors.
Materials and methods

Tissues
We used an in vivo mouse model of mammary development and tumorigenesis to study normal tissue, pregnant and lactating glands, preneoplastic lesions, eight primary adenocarcinomas and organ metastases to the liver and lung. The TM preneoplastic outgrowth lines developed after transplantation of established mouse mammary epithelial cell lines (MMEL) into cleared mammary fat pads of 3-week-old syngenic BALB/cMed mice (Kittrell et al., 1992) . The serially-transplanted outgrowths were removed either as preneoplasias at 8 ± 12 weeks after transplantation or as tumors 5 ± 7 months after transplantation. After removal, the preneoplastic outgrowths, primary adenocarcinomas, and metastases were frozen at 7808C for further analysis. The biological properties of the outgrowth lines are shown in Table 1 .
Epithelial cell isolation from mature virgin mammary tissue
Isolated mammary fat pads were minced and incubated in DMEM medium with 2 mg/ml collagenase A (Boehringer Mannheim, Germany) and 100 U/ml hyaluronidase (Boehringer Mannheim, Germany) at 378C for 3 h and slowly swirled. Afterwards the solution was centrifuged for 5 min at 1000 r.p.m. The supernatant, containing fat and single cells, was discarded and the pellet, containing mammary epithelial cells, was washed in PBS/5% FCS and stored at 7808C for further analysis.
RNA isolation, RT ± PCR and sequencing
Tissues were minced on dry ice before they were treated with a tissue homogenizer (Polytron, Littau, Switzerland) in TRIzol solution (Gibco-BRL, Gaithersburg, MD, USA) with 1 ml per 100 mg of tissue for three times 10 s. After 5 min of incubation at 268C, 0.2 ml of chloroform per 1 ml of TRIzol were added and the solution was shaken vigorously, followed by incubation at 268C for 5 min. After centrifugation for 15 min at 48C and 12 000 g the aqueous phase, containing the total RNA, was precipitated with 0.5 ml of isopropyl alcohol per 1 ml of TRIzol for 10 min at 268C and centrifuged for 10 min at 12 000 g at 48C. The pellets were rinsed with 75% ethanol (1 ml of ethanol per 1 ml of TRIzol reagent used for the initial homogenization), vortexed and centrifuged at 48C for 5 min at 7500 g and ®nally dissolved in RNAse free water and stored at 7808C for further analysis.
Five micrograms of RNA were used for cDNA synthesis using M-MuLV reverse transcriptase (Perking Elmer, Branchburg, NJ, USA) and oligo-dT primers followed by PCR using primers speci®c for dierent SR proteins: SRp20:
5'-GCCGTGTAAGAGTGG, 3'-AAGCTTCCTCCTTCTTGG; hnRNP A1: 5'-GGTGGTCGTGGAGGTGGTT, 3'-CCAAAATCATTGTAGCTTCC, and hnRNP A2: 5'-ACAGTCTGTAAGCTTTCCCC, 3'-CTGAAGCGACTGAGTCCGCG.
The standard form of CD44 mRNA (CD44 std) was detected using PCR primers for constitutive exons 5 and 16: CD44 exon 5:
5'-ACCCCAGAAGGCTACATTTTGC CD44 exon 16: 3'-CTCATAGGACCAGAAGTTGTGG Inclusion of individual alternative exons was monitored using 3' primers speci®c for individual alternative exons and a primer complementary to constitutive exon 5:
CD44v5: (MASV5) 3'-TTGTAGCATGTGGGGTCTCCTCTT, CD44v6: (MASV6) 3'-CCTTCTGTCACATGGGAGTCTTCA, CD44v8: (MASV8) 3'-CACTGAAAGTGGTC CTGTCCTGTT.
All ampli®cation reactions used an ATP-labeled 5' primer. The PCR conditions for all ampli®cations were as follows: 25 ± 35 cycles (see Figure legends) of 948C for 1 min, 598C for 1 min and 728C for 1.5 min. Gel electrophoresis of 35 ml of the 100 ml PCR reaction was performed in 6% denaturing acrylamide gels at 34 ± 40 mA. Expected ampli®cation products are as follows: 142 bp (SRp20), 155 bp (hnRNP A1 without alternative exon 7B), 134 and 170 bp (hnRNP A2 with or without the alternative exon), and 221 bp (CD44 standard lacking any alternative exon). The expected ampli®cation bands for alternatively-spliced CD44 mRNA containing only one variable exon are 207 bp (v5), 209 bp (v6) and 190 bp (v8). pBR 322/HpaII markers were used in all displayed gels for product size determination. Identi®ed ampli®cation products resulting from the inclusion of one or two variable CD44 exons were sequenced to verify identity. After cloning of CD44 PCR products into a pCR 2.1 vector (TA cloning kit, Invitrogen, CA, USA) sequencing of these clones was performed using the thermo sequenase method (Amersham, OH, USA) and CD44 exon speci®c primers mentioned above.
Protein isolation and Western blot
Total cellular protein was isolated from the interphase and phenol phase from the initial homogenate after precipitation of the DNA with 0.3 ml 100% of ethanol per 1 ml of TRIzol used for the initial homogenization. The samples were stored at 268C for 5 min and afterwards centrifuged at 2000 g for 5 min at 48C. The phenol-ethanol supernatant was then precipitated with 1.5 ml isopropyl alcohol per 1 ml TRIzol used for initial homogenization. After storage for 10 min at 268C the protein precipitates were centrifuged at 12 000 g at 48C for 10 min. Protein pellets were washed three times in 0.3 M guanidine hydrochloride in 95% ethanol for 20 min at 268C and centrifuged at 7500 g for 5 min at 48C. The protein pellets were vortexed after the ®nal wash in 2 ml 100% ethanol, stored for 20 min at 268C and ®nally centrifuged at 7500 g for 5 min at 48C. The pellets were resuspended in 1% SDS solution and incubated at 508C for complete dissolution. Insoluble material was removed by centrifugation at 10 000 g for 10 min at 48C. Supernatants were stored for further analysis at 7808C. Gel electrophoresis of 20 mg of total protein was performed using a 10% SDS ± PAGE gel at 100 volts. Afterwards the gels were electroblotted on a PVDF transfer membrane (PolyScreen, NEN Life Science, Boston, MA, USA) at 100 volts for 2.5 h at 48C. After blocking in 5% Blotto/PBST membranes were incubated with mouse IgM mAb104 (1 : 5 dilution), the SRp20 speci®c mouse IgG Ab (1 : 200 dilution) or polyclonal rabbit anti-U2AF Ab 1 : 6000 dilution). The Western blots were stained by chemiluminescence (NEN Life Science) using appropriate horseradish-peroxidase labeled anti IgM antibody for mAb104 (Pierce, Rockford, IL, USA) or anti IgG antibody for SRp20 Ab and U2AF Ab a dilution of 1 : 3000.
